You searched for "radical prostatectomy"

19 results found

Robot assisted radical prostatectomy – could it be gold standard?

Prostate cancer (PCa) is still the second leading cause of cancer-related death in men in the United States. Most of the PCa are organ confined at the time of diagnosis. To watch (observation / active surveillance) or fry (radiotherapy) or...

Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer

Despite prostate cancer being one of the most commonly diagnosed cancers worldwide, there remains a need for high-quality evidence regarding the optimal treatment choice. In this large population-based cohort study, using the PCBaSe Sweden dataset, Sooriakumaran and colleagues identified patients...

Urethral sphincter function before and after radical prostatectomy

This paper from Holland will be useful for urologists involved in radical prostatectomy (RP) for cancer of the prostate. It presents a PubMed search between 1980 and 2012. Twenty-five out of 124 articles were further analysed, mainly English-language papers. Several...

Has laparoscopic radical prostatectomy had its day?

Over recent years there has been a massive uptake in robotic surgery particularly for robot-assisted prostatectomy. The drive for this has been patient and physician led with little in the way of prospective randomised trials showing benefits over established operative...

The importance of assessing frailty in patients prior to radical prostatectomy

This large-scale retrospective study evaluated the short-term postoperative outcomes in patients with localised prostate cancer treated with radical prostatectomy (RP). Both body mass index (BMI) and Charlson comorbidity Index (CCI) are well established indicators of adverse outcomes post major surgery,...

Ureteric injury rates during robot assisted radical prostatectomy

Jhaveri et al. and colleagues have produced a timely report on the incidence of ureteric injuries during robot assisted radical prostatectomy. They reviewed the complications of 6442 consecutive patients treated with robot assisted prostatectomy at the same institution by one...

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy

There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...

Catheters and incontinence after radical prostatectomy: Preparing (but not scaring) men

Every year about 6000 men in the UK undergo radical prostatectomy (RP) for treatment of prostate cancer [1]. Despite surgical advances, RP continues to be associated with significant side-effects including urinary incontinence (UI) [2]. Immediately following removal of the urinary...

Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy

Neutrophil-to-lymphocyte ratio has been shown to be a prognostic factor in a number of different cancers. This is one of the largest studies to date to evaluate its effect on overall survival in patients who have undergone radical prostatectomy (RP)...

Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy

The functional side-effects of both radical prostatectomy and radiotherapy for prostate cancer are well known. The aim of this study was to evaluate if there was a significant worsening in recovery of urinary continence in those undergoing radical prostatectomy followed...

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy

Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...
  • 1 (current)
  • 2